Table 3.
Changes in BCVA and exudative pathology and final outcomes
| Treatment administered | ||||
|---|---|---|---|---|
| PDT + anti-VEGF (n = 24) | PDT (n = 9) | Anti-VEGF (n = 8) | None (n = 7) | |
| Mean BCVA (± SD) | ||||
| Baseline | 65.5 ± 8.9 letters | 74.9 ± 5.3 letters | 65.5 ± 7.4 letters | 77.9 ± 13.2 letters |
| Final visit | 66.4 ± 14.8 letters | 75.2 ± 5.8 letters | 70.8 ± 7.9 letters | 76.9 ± 9.4 letters |
| pa | 0.2317 | 0.6733 | 0.0343 | 0.4004 |
| Mean BCVA change (±S D) | 0.8 ± 11.1 letters | 0.3 ± 3.6 letters | 5.3 ± 4.9 letters | −1.0 ± 13.8 letters |
| Mean CRT (± SD) | ||||
| Baseline | 422.0 ± 161.6 μmb | 335.0 ± 160.2 μm | 473.6 ± 194.8 μm | 300.3 ± 36.0 μm |
| Final visit | 244.9 ± 42.1 μmb | 284.2 ± 132.5 μm | 266.3 ± 60.9 μm | 298.4 ± 54.8 μm |
| pa | <0.0001 | 0.0151 | 0.0156 | 0.5992 |
| SRF and/or IRF (n eyes) | ||||
| Present at baseline | 24 | 8 | 8 | 1 |
| Present at final visit | 6 | 4 | 5 | 1 |
| Subfoveal fluid (n eyes) | ||||
| Present at baseline | 18 | 4 | 7 | 0 |
| Present at final visit | 2 | 1 | 2 | 0 |
| PED (n eyes) | ||||
| Present at baseline | 23 | 8 | 8 | 2 |
| Improved at final visit | 20 | 6 | 6 | 1 |
| Status at final visit | ||||
| Discharged | 2 | 2 | 0 | 3 |
| Monitoring | 12 | 7 | 2 | 4 |
| Fixed interval dosing | 4 | N/A | 0 | N/A |
| Treat-and-extend | 6 | N/A | 6 | N/A |
BCVA best corrected visual acuity, SD standard deviation, CRT central retinal thickness, SRF subretinal fluid, IRF intraretinal fluid, PED pigment epithelial detachment, N/A not applicable
aComparison of baseline and final BCVA and CRT values in the same treatment group (two-tailed Wilcoxon signed rank test)
bMean CRT values calculated from n = 22 eyes